trending Market Intelligence /marketintelligence/en/news-insights/trending/EnTfKMz8UQFcYvToD0o1KQ2 content esgSubNav
In This List

Bellicum Pharmaceuticals director steps down; replacement named

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Bellicum Pharmaceuticals director steps down; replacement named

Frank McGuyer stepped down from Bellicum Pharmaceuticals Inc.'s board, effective Dec. 20, after serving on the board for nine years.

In connection with McGuyer's resignation, the company appointed Judith Klimovsky to its board, effective the same date.

Klimovsky currently serves as executive vice president and chief development officer of Genmab A/S, an international biotechnology company developing antibody therapeutics for cancer.

Houston-based Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company that develops novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders.